These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27777099)

  • 1. Longevity study with low doses of selegiline/(-)-deprenyl and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP).
    Knoll J; Miklya I
    Life Sci; 2016 Dec; 167():32-38. PubMed ID: 27777099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A longevity study with enhancer substances (selegiline, BPAP) detected an unknown tumor-manifestation-suppressing regulation in rat brain.
    Knoll J; Baghy K; Eckhardt S; Ferdinandy P; Garami M; Harsing LG; Hauser P; Mervai Z; Pocza T; Schaff Z; Schuler D; Miklya I
    Life Sci; 2017 Aug; 182():57-64. PubMed ID: 28623006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].
    Miklya I
    Neuropsychopharmacol Hung; 2008 Mar; 10(1):15-22. PubMed ID: 18771016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).
    Miklya I
    Mol Psychiatry; 2016 Nov; 21(11):1499-1503. PubMed ID: 27480491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic enhancer compounds, besides acting on biogenic amine system, influence the glutamate transmission and stress response.
    Knoll J; Zelena D; Timar J; Baghy K; Mervai Z; Miklya I
    Behav Brain Res; 2020 Jan; 378():112290. PubMed ID: 31610214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1-(Benzofuran-2-yl)-2-(3,3,3-trifluoropropyl)aminopentane HCl, 3-F-BPAP, antagonizes the enhancer effect of (-)-BPAP in the shuttle box and leaves the effect of (-)-deprenyl unchanged.
    Knoll J; Miklya I; Knoll B; Yasusa T; Shimazu S; Yoneda F
    Life Sci; 2002 Sep; 71(17):1975-84. PubMed ID: 12175892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study.
    Miklya I; Knoll B; Knoll J
    Life Sci; 2003 Apr; 72(23):2641-8. PubMed ID: 12672509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J
    Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of (-)-para-fluoro-deprenyl on survival and copulation in male rats.
    Dalló J; Knoll J
    Acta Physiol Hung; 1992; 79(2):125-9. PubMed ID: 1304678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.
    Yoneda F; Moto T; Sakae M; Ohde H; Knoll B; Miklya I; Knoll J
    Bioorg Med Chem; 2001 May; 9(5):1197-212. PubMed ID: 11377178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (-)Deprenyl (Selegiline): past, present and future.
    Knoll J
    Neurobiology (Bp); 2000; 8(2):179-99. PubMed ID: 11061214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sexual performance and longevity.
    Knoll J
    Exp Gerontol; 1997; 32(4-5):539-52. PubMed ID: 9315455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.
    Knoll J; Miklya I
    Arch Int Pharmacodyn Ther; 1994; 328(1):1-15. PubMed ID: 7893186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major depression and the synthetic enhancer substances, (-)-deprenyl and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane.
    Gaszner P; Miklya I
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jan; 30(1):5-14. PubMed ID: 16023777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacology of selegiline ((-)deprenyl). New aspects.
    Knoll J
    Acta Neurol Scand Suppl; 1989; 126():83-91. PubMed ID: 2515725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.
    Knoll J
    Pharmacol Toxicol; 1998 Feb; 82(2):57-66. PubMed ID: 9498233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Essential difference between the pharmacological spectrum of (-)-deprenyl and rasagiline.
    Miklya I
    Pharmacol Rep; 2014 Jun; 66(3):453-8. PubMed ID: 24905523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-related decline of various cognitive functions in well-experienced male rats treated with the putative anti-aging compound (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine ((-)BPAP).
    Ernyey AJ; Kassai F; Kozma K; Plangár I; Somfai Z; Miklya I; Gyertyán I
    Geroscience; 2024 Feb; 46(1):417-429. PubMed ID: 37306892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of the synthetic enhancer substances (-)-deprenyl and (-)-BPAP in major depression.
    Gaszner P; Miklya I
    Neuropsychopharmacol Hung; 2004 Dec; 6(4):210-20. PubMed ID: 15825677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.